Cyclo Therapeutics, Inc.
CYTHDelisted Mar 26, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000922247
Cyclo Therapeutics, Inc. was delisted on Mar 26, 2025; its insiders filed their last Form 4 on Mar 3, 2025; 22 institutions reported holding it in 13F filings for Q4 2024, worth $1.33M in total; no superinvestor held it.
13F holders, Q2 2022
Institutional positions in Cyclo Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- 0 vs. Q1 2022
- Shares held
- 402.3K
- −31.8K (−7.3%) vs. Q1 2022
- Total value
- $794.0K
- −$581.0K (−42.3%) vs. Q1 2022
- New holders
- 0
- 2 more added
- Sold out
- 0
- 7 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CYTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 22 | $1.33M |
| Q3 2024 | 19 | $1.80M |
| Q2 2024 | 22 | $2.84M |
| Q1 2024 | 22 | $3.01M |
| Q4 2023 | 23 | $2.06M |
| Q3 2023 | 17 | $682.7K |
| Q2 2023 | 14 | $725.2K |
| Q1 2023 | 16 | $820.2K |
| Q4 2022 | 15 | $1.83M |
| Q3 2022 | 12 | $768.0K |
| Q2 2022 | 13 | $794.0K |
| Q1 2022 | 13 | $1.38M |
| Q4 2021 | 15 | $1.71M |
| Q3 2021 | 13 | $2.23M |
| Q2 2021 | 12 | $2.70M |
| Q1 2021 | 9 | $585.0K |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Cyclo Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 253,765 | $500.0K | 0.00% | −1,300−0.5% | Reduced |
| Renaissance Technologies LLC | 63,986 | $126.0K | 0.00% | −11,801−15.6% | Reduced |
| Geode Capital Management, LLC | 48,316 | $96.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 28,300 | $57.0K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 2,051 | $4.00K | 0.00% | +4+0.2% | Added |
| Tower Research Capital LLC (TRC) | 2,270 | $4.00K | 0.00% | +762+50.5% | Added |
| UBS Group AG | 793 | $2.00K | 0.00% | −1,498−65.4% | Reduced |
| Citigroup Inc | 1,191 | $2.00K | 0.00% | −41−3.3% | Reduced |
| BlackRock Inc. | 362 | $1.00K | 0.00% | −17,841−98.0% | Reduced |
| Morgan Stanley | 443 | $1.00K | 0.00% | −60−11.9% | Reduced |
| Royal Bank of Canada | 746 | $1.00K | 0.00% | 00.0% | Unchanged |
| Captrust Financial Advisors | 100 | $0 | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 13 | – | – | −13−50.0% | Reduced |